Coronary microvascular dysfunction assessment: A comparative analysis of procedural aspects.
Publication details: 2024; ; ISSN:- 1522-1946
- *Coronary Artery Disease
- *Microvascular Angina
- *Myocardial Infarction
- *Myocardial Ischemia
- Aged
- Coronary Artery Disease/dg [Diagnostic Imaging]
- Coronary Artery Disease/th [Therapy]
- Coronary Circulation
- Coronary Vessels/dg [Diagnostic Imaging]
- Female
- Humans
- Male
- Microcirculation
- Microvascular Angina/di [Diagnosis]
- Middle Aged
- Treatment Outcome
- -- Automated
- MedStar Heart & Vascular Institute
- MedStar Washington Hospital Center
- Advanced Cardiac Catheterization Research Fellowship
- Cardiovascular Disease Fellowship
- Journal Article
Item type | Current library | Collection | Call number | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 38520176 | Available | 38520176 |
Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006
BACKGROUND: Full adoption of coronary microvascular dysfunction (CMD) assessment faces challenges due to its invasive nature and concerns about prolonged procedure time and increased contrast and/or radiation exposure. We compared procedural aspects of CMD invasive assessment to diagnostic left heart catheterization (DLHC) in patients with chest pain who were not found to have obstructive coronary artery disease.
CONCLUSION: Compared to DLHC, CMD assessment is safe and requires only slightly additional contrast use (10 mL) and slightly longer fluoroscopy time (2 min) without clinical implications. These findings emphasize the favorable safety and feasibility of invasive CMD assessment. Copyright © 2024 Wiley Periodicals LLC.
METHODS: A total of 227 patients in the Coronary Microvascular Disease Registry were compared to 1592 patients who underwent DLHC from August 2021 to November 2023. The two cohorts were compared using propensity-score matching; primary outcomes were fluoroscopy time and total contrast use.
RESULTS: The participants' mean age was 64.1 +/- 12.6 years. CMD-assessed patients were more likely to be female (66.5% vs. 45.2%, p < 0.001) and have hypertension (80.2% vs. 44.5%, p < 0.001), history of stroke (11.9% vs. 6.3%, p = 0.002), and history of myocardial infarction (20.3% vs. 7.7%, p < 0.001). CMD assessment was safe, without any reported adverse outcomes. A propensity-matched analysis showed that patients who underwent CMD assessment had slightly higher median contrast exposure (50 vs. 40 mL, p < 0.001), and slightly longer fluoroscopy time (6.9 vs. 4.7 min, p < 0.001). However, there was no difference in radiation dose (209.3 vs. 219 mGy, p = 0.58) and overall procedure time (31 vs. 29 min, p = 0.37).
English